UK MPs Warn of Risks from Palantir’s NHS Data Access

UK MPs have raised concerns about Palantir Technologies’ access to identifiable NHS England patient data, calling it a threat to public trust. The controversy centers on the NHS’s decision to grant the US tech firm unrestricted access to patient records as part of its Federated Data Platform (FDP), a project aimed at integrating health datasets to improve care. NHS England insists it has strict policies to protect data, but critics argue the move undermines privacy and transparency, echoing past concerns from a 2021 data-sharing initiative. Public distrust has grown, with recent polling showing 40% of UK citizens distrust Palantir with NHS data, despite the company’s claims it cannot access identifiable records. This tension highlights the ongoing struggle between technological innovation and ethical data governance in public health.

“Palantir fails the trust test. The government should cut it out of our NHS once and for all.”

Historical Precedent: The Care.data Debacle

The current controversy echoes the fallout from the NHS’s failed Care.data program, launched in 2014 to share patient records for research and planning. The initiative faced massive public backlash over fears of data misuse, leading to its termination in 2016. A 2023 study by Dr. Panayiotis Vezyridis analyzed media coverage of Care.data, noting how public distrust in data handling became a target for political and ethical scrutiny. The parallels with Palantir’s FDP suggest a recurring tension between digital modernization and patient privacy, with the NHS now facing similar accusations of overreach. The Care.data debacle highlights the risks of centralized data systems, as seen in the 2021 GP data-sharing plans, which also faced mass opt-outs due to privacy concerns.

NHS England has defended its approach, stating the FDP will respect the National Data Opt-Out, a mechanism allowing patients to refuse data sharing. However, a 2026 Medact briefing warned that while this policy protects individual choice, it could undermine the FDP’s effectiveness, as seen in 2021 when GP data-sharing plans faced mass opt-outs. Critics, including Labour MP Rachael Maskell, argue the NHS’s reliance on opt-outs risks eroding public confidence, especially given Palantir’s controversial role in other sectors. The briefing also noted Trusts struggle to reassure patients aware of Palantir’s global operations, including its work with US immigration authorities and military agencies. These associations amplify concerns about data misuse, even as the NHS insists on strict access controls.

Recent polling underscores public concern. A 2026 survey by the Patients Association found 40% of UK citizens distrust Palantir with NHS data, despite the company’s claims it cannot access identifiable records. This skepticism is amplified by Palantir’s ties to controversial projects, such as its work with US immigration authorities and military agencies, which have drawn scrutiny from civil society groups. Tech equity campaigner Tom Hegarty of Foxglove stated: ‘Palantir fails the trust test. The government should cut it out of our NHS once and for all.’ These concerns are validated by a 2024 study in Social Science & Medicine, which noted public-private data partnerships often face ‘ethical clashes’ over data ownership and transparency. The FDP’s reliance on external contractors, including Palantir, raises accountability questions, as highlighted by Liberal Democrat MP Martin Wrigley, who called the project’s data security measures ‘cavalier.’

“cavalier”

Trend Connection: Private Tech in Public Services

The NHS’s collaboration with Palantir reflects a broader trend of private tech firms expanding into public sector data systems. A 2024 study in Social Science & Medicine noted such partnerships often face ‘ethical clashes’ over data ownership and transparency. The FDP’s reliance on external contractors, including Palantir, raises accountability questions, as highlighted by Liberal Democrat MP Martin Wrigley, who called the project’s data security measures ‘cavalier.’ This trend highlights the growing challenge of balancing innovation with privacy in an era of increasing data-driven governance. The NHS’s decision to grant Palantir unrestricted access to patient data aligns with a pattern of private sector involvement in public services, raising concerns about prioritizing corporate interests over patient autonomy.

As the NHS navigates its digital transformation, the Palantir controversy underscores the need for transparent data governance. While the FDP promises efficiency gains, its success hinges on rebuilding public trust—a task complicated by Palantir’s controversial reputation. The debate over data access is not just technical but deeply political, reflecting broader tensions between technological progress and individual rights. For the NHS, the challenge is to ensure data integration serves patient care without compromising the trust it seeks to uphold. Without clear safeguards and public engagement, the FDP risks becoming another casualty of the data trust crisis that has plagued the NHS for over a decade. The path forward requires reevaluating how data is shared, who controls it, and how patients are informed and empowered in the process.